Answers are grounded in this paper and cite their sources.
The envelope‐anchored trimeric spike protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mediates the attachment and entry of the virus within human cells by utilizing the angiotensin converting enzyme 2 (ACE2) as a receptor, present in the epithelial cells of the upper respiratory tract and lungs. The ACE2 interaction interface with the SARS‐CoV‐2 spike protein was utilized to design an ACE2‐derived peptide sequence (FD11) that targeted the viral spike protein. It was found to be non‐cell penetrating, while in vivo studies revealed the non‐cytotoxic nature of the peptide molecule. The minimum effective concentration of the peptide was found to be 10 μM with 95% cell viability in Vero E6 cell line. The IC 50 of the peptide was found to be around 6.4 μM. Treatment of the peptide in SARS‐CoV‐2 infected Vero E6 cells was found to decrease the infectivity as compared to control. This presents a simple approach where host‐pathogen protein interaction‐interface derived peptides can be used for binding with substrate macromolecules to target and modulate pathogen infectivity.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: